Literature DB >> 30380941

Public Understanding and Awareness of Isotretinoin Use and Safety in Al Ahsa, Eastern Saudi Arabia.

Nancy S Younis1, Nourah Yousef Al-Harbi2.   

Abstract

BACKGROUND: Acne vulgaris, a chronic inflammatory disease, is among the most common dermatologic conditions worldwide. In Saudi Arabia, Isotretinoin is commonly used to treat mild acne even without prescription.
OBJECTIVE: To explore the practice and knowledge of community in Saudi Arabia regarding dispensing, counseling practices, and safety of isotretinoin-containing products.
METHODS: A cross-sectional survey, using a self-administered questionnaire, was conducted in 3 sections: demographics, self-medication attitude (in the form of self Isotretinoin use), and identifying the side effects associated with the use of isotretinoin.
RESULTS: A total of 1069 participated in the study. Around half of the participants (44.2%) used isotretinoin with only mild acne as their first choice, which is contrary to the recommended guidelines. Virtually one-fifth of the participants did not examine the lipid profile, liver enzymes, and blood glucose level before isotretinoin use. Not many participants identified lipid (58.7%) and liver (44.1%) depression (53.3%), inflammatory bowel disease (75.9%), osteoporosis (60.3%), and sunburns (36.3%) as risks allied with isotretinoin use. Most participants (88.9%) appropriately recognized teratogenicity as the greatest hazard concomitant with the use of isotretinoin. Nevertheless, 20% of the women did not know that they must cease the drug at least 6 months before pregnancy.
CONCLUSION: This study shows that community residents are not satisfactorily aware of the proper use and jeopardies of isotretinoin. Therefore, greater consideration ought to be dedicated to augment the safe use of isotretinoin. We recommend the implementation of tools to enhance the safe use of isotretinoin and the imposition of more effective regulations to limit nonprescribed isotretinoin dispensing in Saudi Arabia.

Entities:  

Keywords:  acne; community knowledge; counseling practices; isotretinoin

Mesh:

Substances:

Year:  2018        PMID: 30380941     DOI: 10.1177/2168479018807677

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  6 in total

1.  Patients' Knowledge and Information Needs about Isotretinoin Therapy Use in Jordan.

Authors:  Anan S Jarab; Sayer Al-Azzam; Shriefa Almutairi; Tareq L Mukattash
Journal:  Int J Clin Pract       Date:  2022-02-14       Impact factor: 3.149

2.  Females' Knowledge and Use of Isotretinoin (Roaccutane) in the Western Region of Saudi Arabia.

Authors:  Kholoud Mohammed A Bakheet; Rand G Alghanemi; Alya M Alsiyoufi; Mohammed Abduljabbar; Jehad Hariri
Journal:  Cureus       Date:  2020-12-18

3.  Dermatologists' Knowledge and Attitudes Toward Dry Eye Disease, Refractive Surgery, and Contact Lenses When Prescribing Isotretinoin in Saudi Arabia.

Authors:  Ahmed Basheikh; Asmaa Alattas; Reem Alshareef; Ashjan Bamahfouz
Journal:  Clin Ophthalmol       Date:  2020-12-24

4.  Perceived risks of over-the-counter medication use among pregnant Saudi mothers: A cross-sectional study.

Authors:  Ashwaq Ayidh M Alosaimi; Sahar M Zamzam; Daniel Joseph E Berdida; Hazel N Villagracia
Journal:  J Taibah Univ Med Sci       Date:  2022-03-20

5.  Awareness of isotretinoin use and Saudi FDA pregnancy prevention program in Riyadh, Saudi Arabia: A cross-sectional study among female patients.

Authors:  Alnada Abdalla Mohamed Ibrahim; Amal Almotiry Alshatri; Salem Alsuwaidan; Lulu Almutairi; Nasser Aljasser; Mansour Adam Mahmoud; Afnan Alaseeri; Abrar Almonysir; Badraa Alotaibi; Batoul Alrasheed; Maram Alfawaz
Journal:  Saudi Pharm J       Date:  2021-04-23       Impact factor: 4.330

6.  Awareness on Teratogenic Effects of Isotretinoin and Compliance with Precautionary Measures among Women of Childbearing Age in Makkah Province, Saudi Arabia.

Authors:  Rawan Al-Mekhlafi; Rawabi E Attiyah; Yara R Haddad; Louai A Salah
Journal:  Obstet Gynecol Int       Date:  2021-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.